Evidence map›Paper›PMID 39902960›Full record

ArticleJournal of virology2025

Enhancing the solubility of SARS-CoV-2 inhibitors to increase future prospects for clinical development.

Ariel J Kuhn, Victor K Outlaw, Tara C Marcink, Zhen Yu, Megan C Mears, Maria N Cajimat, Dale F Kreitler, Payton R Cleven, Jee Ching Mook, Dennis A Bente and 3 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Journal of virology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors.

Ariel J Kuhn *Department of Chemistry, University of Wisconsin, Madison, Wisconsin, USA.ORCID 0000-0003-1535-8614
Victor K Outlaw *Department of Chemistry, University of Wisconsin, Madison, Wisconsin, USA.
Tara C Marcink *Center for Host-Pathogen Interaction, Columbia University Medical Center, New York, New York, USA.ORCID 0000-0003-4295-1229
Zhen YuDepartment of Chemistry, University of Wisconsin, Madison, Wisconsin, USA.
Megan C MearsGalveston National Laboratory, University of Texas Medical Branch, Galveston, Texas, USA.
Maria N CajimatGalveston National Laboratory, University of Texas Medical Branch, Galveston, Texas, USA.
Dale F KreitlerCenter for BioMolecular Structure, NSLS-II, Brookhaven National Laboratory, Upton, New York, USA.
Payton R ClevenDepartment of Chemistry, University of Wisconsin, Madison, Wisconsin, USA.
Jee Ching MookDepartment of Chemistry, University of Wisconsin, Madison, Wisconsin, USA.
Dennis A BenteGalveston National Laboratory, University of Texas Medical Branch, Galveston, Texas, USA.
Matteo PorottoCenter for Host-Pathogen Interaction, Columbia University Medical Center, New York, New York, USA.ORCID 0000-0003-3866-9220
Samuel H GellmanDepartment of Chemistry, University of Wisconsin, Madison, Wisconsin, USA.ORCID 0000-0001-5617-0058
Anne MosconaCenter for Host-Pathogen Interaction, Columbia University Medical Center, New York, New York, USA.ORCID 0000-0002-1796-8320

Funding

X-ray Scattering Technology CoreP30GM133893 · NIGMS · BROOKHAVEN SCIENCE ASSOC-BROOKHAVEN LAB · PI Lin Yang · 2019 to 2026
$38.6M
Protein Recognition by Peptidic FoldamersR01GM056414 · NIGMS · UNIVERSITY OF WISCONSIN-MADISON · PI GELLMAN, SAMUEL H. · 1997 to 2023
$6.5M
Engineering protease-resistant antiviral peptide inhibitors for SARS-CoV-2R01AI160961 · NIAID · COLUMBIA UNIVERSITY HEALTH SCIENCES · PI MOSCONA, ANNE · 2021 to 2025
$3.6M
Fusion inhibitors that block host-to-host transmission of SARS-CoV-2R01AI160953 · NIAID · COLUMBIA UNIVERSITY HEALTH SCIENCES · PI POROTTO, MATTEO · 2021 to 2025
$3.6M
Structure-guided design of protease-resistant, lipopeptide inhibitors of SARS-CoV-2F32AI176876 · NIAID · UNIVERSITY OF WISCONSIN-MADISON · PI KUHN, ARIEL JADE · 2023 to 2025
$168k
Structure-Guided Design of Peptidomimetic Inhibitors of Paramyxoviral FusionF32GM122263 · NIGMS · UNIVERSITY OF WISCONSIN-MADISON · PI OUTLAW, VICTOR KENNETH · 2017 to 2017
$57k
NIAID NIH HHS F32 AI176876NIAID NIH HHS R01 AI160953NIAID NIH HHS R01 AI160961NIGMS NIH HHS F32 GM122263NIGMS NIH HHS P30 GM133893NIGMS NIH HHS R01 GM056414
6 · The paper itself

Abstract

SARS-CoV-2 poses an ongoing threat to human health as variants continue to emerge. Several effective vaccines are available, but a diminishing number of Americans receive the updated vaccines (only 22% received the 2023 update). Public hesitancy towards vaccines and common occurrence of "breakthrough" infections (i.e. IMPORTANCE: Despite the existence of vaccines for SARS-CoV-2, the constant evolution of new variants and the occurrence of breakthrough infections highlight the need for new and effective antiviral approaches. We have shown that lipopeptides designed to bind a conserved region on the SARS-CoV-2 spike protein can effectively block viral entry into cells and thereby block infection. To support the feasibility of using this approach in humans, we re-designed these lipopeptides to be more soluble, using information about the structure of the spike protein interacting with the peptides to modify the peptide chain. The new peptides are effective against both SARS-CoV-2 and MERS. The lipopeptides described here could serve as treatment for people who are unvaccinated or who experience breakthrough infections, and the approach to increasing solubility can be applied in a broad spectrum approach to treating infections with emerging viruses.

Indexed as

Antiviral AgentsCOVID-19 Drug TreatmentLipopeptidesSARS-CoV-2Spike Glycoprotein, CoronavirusCOVID-19HumansSolubilityVirus InternalizationAntiviral AgentsLipopeptidesSpike Glycoprotein, Coronavirusspike protein, SARS-CoV-2antiviralcrystal structureheptad repeatsinhibitorslipopeptidepeptide designSARS-CoV-2solubilityviral fusion

Identifiers

PMID39902960
PMCPMC11915835

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.